Skip to main content
SpringerLink
Log in

Systemischer Lupus erythematodes durch Tumornekrosefaktor-Blocker – Eine seltene Nebenwirkung einer Uveitis-intermedia-Therapie

Systemic lupus erythematosus induced by tumor necrosis fractor inhibitor—A rare side effect of intermediate uveitis treatment

  • Kasuistiken
  • Published:
Die Ophthalmologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. De Bandt M (2019) Anti-TNF-alpha-induced lupus. Arthritis Res Ther 21(1):235

    Article  Google Scholar 

  2. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491–500 (discussion 500)

    Article  Google Scholar 

  3. Jaffe GJ, Dick AD, Brezin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943

    Article  CAS  Google Scholar 

  4. Katz U, Zandman-Goddard G (2010) Drug-induced lupus: an update. Autoimmun Rev 10(1):46–50

    Article  CAS  Google Scholar 

  5. Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192

    Article  CAS  Google Scholar 

  6. Nussenblatt RB (1990) The natural history of uveitis. Int Ophthalmol 14(5–6):303–308

    Article  CAS  Google Scholar 

  7. Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M (2013) Biologics-induced autoimmune diseases. Curr Opin Rheumatol 25(1):56–64

    Article  CAS  Google Scholar 

  8. Sieiro Santos C, Álvarez Castro C, Moriano Morales C, Díez Álvarez E (2021) Anti-TNF-alpha-induced lupus syndrome. Z Rheumatol. https://doi.org/10.1007/s00393-021-00983-8

    Article  PubMed  Google Scholar 

  9. Suhler EB, Jaffe GJ, Fortin E et al (2021) Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 128(6):899–909. https://doi.org/10.1016/j.ophtha.2020.10.036

    Article  PubMed  Google Scholar 

  10. Aringer M, Brinks R, Dörner T et al (2021) European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis 80(6):775–781

    Article  CAS  Google Scholar 

  11. Yoshikawa N, Matsubara E, Yamamoto M et al (2020) Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-TNF-alpha and IL‑6 therapy in a patient with rheumatoid arthritis. Intern Med 59(20):2611–2618

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Augenklinik, Universitätsklinikum Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland

    Janine Lenk FEBO, Egbert Matthé & Lutz E. Pillunat

  2. Bereich Rheumatologie, Medizinische Klinik und Poliklinik III und UniversitätsCentrum für Autoimmun und Rheumatische Erkrankungen (UCARE), Universitätsklinikum und Medizinische Fakultät Carl Gustav Carus, TU Dresden, Dresden, Deutschland

    Martin Aringer

Authors
  1. Janine Lenk FEBO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Egbert Matthé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lutz E. Pillunat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Aringer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janine Lenk FEBO.

Ethics declarations

Interessenkonflikt

M. Aringer: Advisory boards Abbvie, MSD, Pfizer, Vortragshonorare AbbVie,HEXAL, Pfizer. MSD, UCB. J. Lenk, E. Matthé und L.E. Pillunat geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lenk, J., Matthé, E., Pillunat, L.E. et al. Systemischer Lupus erythematodes durch Tumornekrosefaktor-Blocker – Eine seltene Nebenwirkung einer Uveitis-intermedia-Therapie. Ophthalmologie 119, 851–854 (2022). https://doi.org/10.1007/s00347-021-01481-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-021-01481-7

Search

Navigation